Stratec (SBS) Health Care Conference summary

Business model and technology

• Customizes proprietary technology for OEM partners, integrating development and manufacturing for recurring revenue streams.

• Maintains strong IP position, requiring minimum purchase commitments from partners.

• Focuses on automation in diagnostics, with expertise in molecular diagnostics, immunoassay, and sample prep.

• Nearly half of the 1,500 employees work in R&D, supporting innovation and technology seeding.

• Manufacturing footprint spans Europe and the US, with specialization in both instruments and consumables.

Market position and recurring revenue

• 50,000 analyzer systems installed globally, generating significant recurring revenue from consumables and service parts.

• Recurring revenue from consumables and maintenance parts accounted for 43% of 2024 revenues.

• Partners generate €3–5 billion in downstream revenues using these instruments, while the company earns €250–300 million.

• Instrument sales declined in 2024 due to COVID-19 overcapacity, but service and consumables sales remained strong.

• Replacement cycle and maintenance are increasingly important as customers delay new instrument purchases.

Financial performance and outlook

• Achieved a 13.13% CAGR in top-line growth since going public in 1998.

• 2024 saw a shift: instruments made up only 32% of revenue, with consumables and service parts at 43%.

• Expects low to mid single-digit sales growth and an adjusted EBIT margin of 10–12% in 2025, down from 13% in 2024.

• Cost discipline and inventory management are key focuses, with ongoing efforts to improve BOM costs and negotiate price increases.

• M&A pipeline is active, with a focus on consolidation and leveraging recent acquisitions.